Clinical characteristics of nateglinide response as assessed by insulinogenic indices: Preliminary study to determine an optimal indication for nateglinideMORI, Yutaka; ISHII, Hirotaka; HIKITA, Miho et al.Advances in therapy. 2003, Vol 20, Num 6, pp 352-359, issn 0741-238X, 8 p.Article

Substrate specificity of the nateglinide/H⁺ cotransport system for phenolic acidsSAITO, Yoshitaka; ITAGAKI, Shirou; OTSUKA, Yukio et al.Journal of agricultural and food chemistry (Print). 2005, Vol 53, Num 15, pp 6100-6104, issn 0021-8561, 5 p.Article

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideKALLIOKOSKI, Annikka; BACKMAN, Janne T; NEUVONEN, Pertti J et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 11, pp 937-942, issn 1744-6872, 6 p.Article

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideWEI ZHANG; HE, Yi-Jing; HU, Dong-Li et al.British journal of clinical pharmacology. 2006, Vol 62, Num 5, pp 567-572, issn 0306-5251, 6 p.Article

Treatment of Patients over 64 years of age with type 2 diabetes: Experience from nateglinide pooled database retrospective analysisDEL PRATO, Stefano; HEINE, Robert J; KEILSON, Leonard et al.Diabetes care. 2003, Vol 26, Num 7, pp 2075-2080, issn 0149-5992, 6 p.Article

Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjectsLUZIO, Stephen D; ANDERSON, Denise M; OWENS, David R et al.The Journal of clinical endocrinology and metabolism. 2001, Vol 86, Num 10, pp 4874-4880, issn 0021-972XArticle

Repaglinide versus nateglinide monotherapy: A randomized, multicenter studyROSENSTOCK, Julio; HASSMAN, David R; MADDER, Robert D et al.Diabetes care. 2004, Vol 27, Num 6, pp 1265-1270, issn 0149-5992, 6 p.Article

Pharmacokinetics and metabolism of nateglinide in humansWEAVER, Margaret L; ORWIG, Barbara A; RODRIGUEZ, Lolita C et al.Drug metabolism and disposition. 2001, Vol 29, Num 4, pp 415-421, issn 0090-9556, 1Article

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinideSCHEEN, André J.Clinical pharmacokinetics. 2007, Vol 46, Num 2, pp 93-108, issn 0312-5963, 16 p.Article

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjectsSABIA, Helene; SUNKARA, Gangadhar; LIGUEROS-SAYLAN, Monica et al.European journal of clinical pharmacology. 2004, Vol 60, Num 6, pp 407-412, issn 0031-6970, 6 p.Article

Improvement of insulin resistance by a new insulin secretagogue, nateglinide: analysis based on the homeostasis modelSHIBA, Teruo.Diabetes research and clinical practice. 2003, Vol 62, Num 2, pp 87-94, issn 0168-8227, 8 p.Article

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjectsKARARA, A. H; DUNNING, B. E; MCLEOD, J. E et al.Journal of clinical pharmacology. 1999, Vol 39, Num 2, pp 172-179, issn 0091-2700Article

Relative Fasting Bioavailability of Two Formulations of Nateglinide 60 mg in Healthy Male Chinese Volunteers: An Open-Label, Randomized-Sequence, Single-Dose, Two-Way Crossover StudyYUBING ZHU; QIAN ZHANG; CUIXIA YU et al.Clinical therapeutics. 2012, Vol 34, Num 7, pp 1505-1510, issn 0149-2918, 6 p.Article

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metforminDEROSA, G; D'ANGELO, A; FOGARI, E et al.Journal of clinical pharmacy and therapeutics (Print). 2009, Vol 34, Num 1, pp 13-23, issn 0269-4727, 11 p.Article

Thermodynamic relationships between nateglinide polymorphsBRUNI, G; BERBENNI, V; MILANESE, C et al.Journal of pharmaceutical and biomedical analysis. 2009, Vol 50, Num 5, pp 764-770, issn 0731-7085, 7 p.Article

A validated stability indicating LC method for nateglinidePATHARE, D. B; JADHAV, A. S; SHINGARE, M. S et al.Drug development and industrial pharmacy. 2007, Vol 33, Num 5, pp 551-557, issn 0363-9045, 7 p.Article

Nateglinide quantification in rabbit plasma by HPLC : Optimization and application to pharmacokinetic studySANKALIA, Jolly M; SANKALIA, Mayur G; SUTARIYA, Vijay B et al.Journal of pharmaceutical and biomedical analysis. 2007, Vol 44, Num 1, pp 196-204, issn 0731-7085, 9 p.Article

B-cell function in mild type 2 diabetic patients : Effects of 6-month glucose lowering with nateglinideMARI, Andrea; GASTALDELLI, Amalia; FOLEY, James E et al.Diabetes care. 2005, Vol 28, Num 5, pp 1132-1138, issn 0149-5992, 7 p.Article

Acute and long-term effects of nateglinide on insulin secretory pathwaysBALL, Andrew J; FLATT, Peter R; MCCLENAGHAN, Neville H et al.British journal of pharmacology. 2004, Vol 142, Num 2, pp 367-373, issn 0007-1188, 7 p.Article

Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitusFONSECA, V. A; KELLEY, D. E; CEFALU, W et al.Metabolism, clinical and experimental. 2004, Vol 53, Num 10, pp 1331-1335, issn 0026-0495, 5 p.Article

Control of postprandial hyperglycemia: Optimal use of short-acting insulin secretagoguesCARROLL, Mary F; IZARD, Ahmad; RIBONI, Katrina et al.Diabetes care. 2002, Vol 25, Num 12, pp 2147-2152, issn 0149-5992, 6 p.Article

Differential interactions of nateglinide and repaglinide on the human β-cell sulphonylurea receptor 1HANSEN, Ann Maria K; CHRISTENSEN, Inge T; HANSEN, John Bondo et al.Diabetes (New York, NY). 2002, Vol 51, Num 9, pp 2789-2795, issn 0012-1797, 7 p.Article

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteersYU CHENG; GUO WANG; WEI ZHANG et al.European journal of clinical pharmacology. 2013, Vol 69, Num 3, pp 407-413, issn 0031-6970, 7 p.Article

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance : Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) TrialCALIFF, Robert M; BOOLELL, Mitradev; HAFFNER, Steven M et al.The American heart journal. 2008, Vol 156, Num 4, pp 623-632, issn 0002-8703, 10 p.Article

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity : Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1DUFFY, Nicola A; GREEN, Brian D; IRWIN, Nigel et al.European journal of pharmacology. 2007, Vol 568, Num 1-3, pp 278-286, issn 0014-2999, 9 p.Article